Updated European guidelines for metabolic dysfunction–associated steatotic liver disease stressed a higher risk in people ...
Non-alcoholic fatty liver disease (NAFLD), recently reclassified as metabolic dysfunction-associated steatotic liver disease ...
Salivary biomarkers could be the way forward in diagnosing liver fibrosis thanks to a partnership between Griffith University ...
Supported by positive data from Phase 2b FASCINATE-2 trial of denifanstat in patients with MASH Preparations are ongoing to ...
In NAFLD-related cirrhosis, liver histology may no longer show inflammation or even steatosis, and this likely represents the largest proportion of cases often referred to as "cryptogenic cirrhosis." ...
such as high blood pressure and hepatic steatosis (fatty liver disease). "The originality of our study lies in showing that the central nervous system, via sympathetic nerves, can control CREB and ...
Akero Therapeutics has a solid cash runway and financial stability to support ongoing trials for its drug candidate. Read ...
The paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH)Data is confirmed using 3 objective ...
Bristol-Myers Squibb received FDA's approval for Cobenfy, which is poised to be a game changer in the treatment of ...
Whether moderate doses of UDCA slow the progression of PSC-related liver disease remains unclear and ... such as standard liver function tests and liver histology, have proved to be inadequate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback